within Pharmacolibrary.Drugs.ATC.C;

model C01EB24
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.05,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00065,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Mavacamten is a selective, allosteric inhibitor of cardiac myosin ATPase, developed primarily for the treatment of hypertrophic cardiomyopathy (HCM). It works by decreasing excessive contractility and improving cardiac relaxation. Mavacamten (marketed as Camzyos) is approved for use in adults with symptomatic obstructive HCM.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy volunteers and patients with HCM after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Wu, X, et al., &amp; Zhang, J (2024). Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes. <i>Clinical and translational science</i> 17(7) e13877–None. DOI:<a href=&quot;https://doi.org/10.1111/cts.13877&quot;>10.1111/cts.13877</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39014868/&quot;>https://pubmed.ncbi.nlm.nih.gov/39014868</a></p></li><li><p>Chiang, M, et al., &amp; Merali, S (2023). Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model. <i>Journal of clinical pharmacology</i> 63(11) 1275–1282. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2298&quot;>10.1002/jcph.2298</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37376778/&quot;>https://pubmed.ncbi.nlm.nih.gov/37376778</a></p></li><li><p>Chiang, M, et al., &amp; Gaohua, L (2023). Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype. <i>Clinical pharmacology and therapeutics</i> 114(4) 922–932. DOI:<a href=&quot;https://doi.org/10.1002/cpt.3005&quot;>10.1002/cpt.3005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37467157/&quot;>https://pubmed.ncbi.nlm.nih.gov/37467157</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01EB24;
